IA2030 – IG 2.2 Provide access to all vaccines

Count

Indicator selected for global monitoring for IImmunization Agenda 2030 Impact Goal Indicator 2.2:

Introduction of new or underutilized vaccines in low- and middle-income countries. Global, regional, and country partners can use findings from this indicator to identify countries that are remaining to introduce WHO recommended vaccines in order to focus efforts to ensure equitable access to vaccines. The indicator will help to assess whether there are opportunities to support country vaccination introductions for new and underutilized vaccines. Further in-depth evaluation or root cause analysis could be considered to determine barriers to vaccine introduction for the countries that have not yet introduced WHO recommended vaccines.

Number of introductions of new or under-utilized vaccines in low- and middle-income countries based on most recent World Bank income status classification at the time of reporting. Year of introduction is based on the year the vaccine was first reported, including cases where a vaccine was introduced and was suspended or not administered. • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in all countries: HepB birth dose, Hib, HPV, IPV2, MCV2, PCV, Rotavirus, Rubella, DTP booster (currently reporting the fourth dose regardless of what age it was administered), and COVID-19 (interim recommendation). o Only national introductions are included for the indicator reporting o Except for DTP booster, all other vaccines are included based on WHO recommendations () - this is to be revisited in the future to further align with the WHO recommendations • Vaccines included in this indicator that are recommended by WHO for use in national immunization schedules in countries in certain geographic region(s), in some high-risk populations, or in immunization programmes with certain characteristics: YF, JE, MenA, multivariate meningitis, HepA, influenza, varicella, and mumps. o Typhoid, cholera, dengue, and rabies are included in the Framework for Action as part of the indicator reporting but are not being reported on pending further discussions around indicator revision. • Baseline year: 2020 (introductions made up to 2019 are not included in the IG 2.2 reporting) • Target: At least 500 cumulative vaccine introductions in low- and middle-income countries by 2030 (including current new or under-utilized vaccines as well as vaccines that will be recommended over the decade)

Vaccine introduction: Addition of a vaccine to the national immunization schedule and officially reported by the country (excludes vaccines used only in the private sector that are not in national immunization schedule; includes vaccines in national immunization schedules that are used in at risk populations, e.g., seasonal influenza). New or underutilized vaccines: Vaccines that have not yet been introduced into national immunization schedules in all countries where recommended by WHO.

Low- and middle-income countries among WHO Member States

National immunization programme

Process

Step 1: Count the number of introductions of new or under-utilized vaccines in low- and middle-income countries among WHO Member States. • Only the low- and middle-income countries based on most recent World Bank income status classification at the time of reporting should be included.

Sum

N/A

N/A

Annual

Annual(includes historical data updates)

vpdata@who.int

7775

Vaccine may have been introduced earlier than reported but reporting is based on official data from the WHO Member States. Although countries report having introduced select vaccines in national immunization schedules, it does not mean children are vaccinated.